Common questions about Xalkori (FAQ)
Q: What specific types of cancer are Xalkori approved to treat?
A: According to official product information, Xalkori is approved to treat specific types of non-small cell lung cancer (NSCLC) that test positive for certain gene changes (ALK or ROS1). It is also approved for use in children and adolescents to treat two types of tumors that are ALK-positive: anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumors (IMT).
Q: What does it mean for a tumor to have an 'ALK-positive' or 'ROS1-positive' gene alteration?
A: When a tumor is described as ALK-positive or ROS1-positive, it means the cancer cells contain genetic alterations that make these proteins abnormally active. This overactivity is believed to promote continuous signals that support uncontrolled cell growth. Xalkori is a targeted therapy designed to block these specific signals.
Q: Are the gastrointestinal side effects like diarrhea common, and how long do they usually last?
A: Gastrointestinal issues, such as diarrhea and nausea, are listed as very common side effects in regulatory documents. While these effects can be challenging at the start of treatment, official information suggests that, for many patients, these side effects may lessen or improve over time.
Q: What specific blood tests are used to monitor liver function during Xalkori treatment?
A: Because Xalkori can affect the liver, regular blood monitoring is part of the required safety surveillance. Liver function is typically monitored using blood tests designed to measure specific liver enzymes, such as transaminases, and total bilirubin levels.
Q: What are the official warning signs of a serious lung problem, such as pneumonitis, associated with Xalkori?
A: Official regulatory information warns that serious lung problems, like pneumonitis (inflammation of the lungs), have been reported with Xalkori use. Warning signs can include new or worsening symptoms such as trouble breathing (dyspnea), cough (with or without mucus), or fever.
Q: How quickly do changes in vision typically start after a patient begins taking Xalkori?
A: Changes in vision are a common side effect of Xalkori. According to the FDA label, these visual disturbances generally start quickly, often being noticed within the first week of starting the medication.
Q: Does Xalkori cause peripheral neuropathy (numbness or tingling) in the hands or feet?
A: Yes, peripheral neuropathy, which includes symptoms like numbness, tingling, or pain in the arms or legs, is a common adverse reaction reported in clinical studies. This finding is consistently reported across clinical studies of the medication.
Q: Can Xalkori treatment affect fertility or the ability to have children in men or women?
A: Official documents indicate that Xalkori may cause fertility problems in both males and females. These potential effects on reproductive ability could impact a patient's capacity to have children.
Q: Does Xalkori make the skin more sensitive to sun exposure (photosensitivity)?
A: Xalkori can cause the skin to become unusually sensitive to sunlight, a condition known as photosensitivity. Regulatory guidance highlights the importance of using protective measures, such as clothing and sunscreen, and avoiding prolonged sun exposure.
Q: What is the reported frequency of rare but serious side effects like fatal liver injury in official data?
A: While elevated liver enzymes are common, serious liver injury (hepatotoxicity) is a rare but potential risk. Regulatory data indicates that fatal hepatotoxicity has occurred in 0.1% of patients treated with Xalkori across clinical trials.
Q: Does Xalkori require monitoring for low blood cell counts, such as neutropenia or lymphopenia?
A: Xalkori can cause decreases in certain blood components, specifically white blood cell counts like neutropenia and lymphopenia. Due to this potential side effect, regulatory documents note that regular blood tests are necessary to monitor these counts during treatment.
Q: Is it normal to experience dizziness while undergoing Xalkori treatment?
A: Yes, dizziness is listed as a common adverse reaction in the official product information for Xalkori. This means a notable percentage of patients in clinical studies reported experiencing this effect.
Q: Can Xalkori cause changes in weight, either gain or loss?
A: Changes in body weight have been reported as adverse reactions associated with Xalkori use. Regulatory documents list both unusual weight gain and weight loss as possible effects.
Q: What pre-existing heart conditions might make a patient ineligible to take Xalkori?
A: The drug label advises careful consideration of the benefits and risks before starting treatment in patients with certain pre-existing heart conditions. These conditions include a history of slow heart rate (bradycardia) or a predisposition for QTc prolongation, a change in the heart’s electrical activity. Severe cardiac failure has also been reported in some patients.
Q: Can Xalkori be used by patients who have a history of severe kidney problems?
A: According to official prescribing information, Xalkori can be used in patients with severe kidney (renal) impairment who are not on dialysis. However, the regulatory documents indicate that a dose reduction and careful monitoring of the patient's condition are necessary in these cases.
Q: Is Xalkori generally considered safe for use in the elderly patient population?
A: Based on regulatory information, a starting dose adjustment is not generally required for elderly patients. This is based on studies showing that age alone does not typically necessitate a change in the initial dosing schedule.
Q: What precautions regarding pregnancy and contraception are outlined for females taking Xalkori?
A: Xalkori has the potential to cause harm to an unborn baby. Therefore, official guidelines state that females who can become pregnant are required to use effective contraception throughout the duration of therapy and for at least 45 days after the final dose.
Q: What is the guidance regarding breastfeeding or lactation while receiving Xalkori?
A: It is not known whether Xalkori passes into breast milk. Regulatory guidance indicates that patients should not breastfeed at any time during treatment and for 45 days after the final dose of the medication.
Q: Are there any known absolute contraindications for taking Xalkori?
A: Absolute contraindications are conditions where the drug should not be used under any circumstances. According to official product labels, this includes having a known hypersensitivity (severe allergic reaction) to crizotinib, or having pre-existing severe hepatic (liver) impairment.
Q: Can Xalkori interact with any over-the-counter pain relievers?
A: Xalkori has the potential to interact with other medicines processed by the CYP3A enzyme in the liver or those that affect heart rhythm. Regulatory documents suggest that all over-the-counter medicines, vitamins, and supplements be discussed with a healthcare professional to identify potential interactions.
Q: Does Xalkori interact with common dietary supplements or vitamins?
A: Yes, Xalkori is known to interact with certain supplements and herbal remedies. Specifically, regulatory information highlights interactions with supplements containing grapefruit extract and the herbal product St. John's wort.
Q: Is Xalkori approved for the treatment of Inflammatory Myofibroblastic Tumor (IMT)?
A: Xalkori is approved for the treatment of ALK-positive Inflammatory Myofibroblastic Tumor (IMT) in children and adolescents. This is in addition to its primary indication for non-small cell lung cancer.
Q: What is the role of Xalkori in treating Systemic Anaplastic Large Cell Lymphoma (ALCL)?
A: Yes, Xalkori is approved for the treatment of ALK-positive Systemic Anaplastic Large Cell Lymphoma (ALCL) in children and adolescents. This indication is supported by its targeted mechanism against the ALK protein.
Q: Is it necessary to have regular eye exams while taking Xalkori?
A: Due to the risk of visual disturbances and severe visual loss, regulatory information recommends a monthly assessment of visual symptoms. Any new or worsening visual symptoms may require consultation with a specialist for further evaluation.
Q: Are there any specific concerns about using Xalkori in pediatric patients?
A: Specific safety concerns for pediatric patients include a high incidence of gastrointestinal toxicity, such as vomiting and diarrhea, and low blood cell counts (neutropenia and lymphopenia). These findings are highlighted in official product safety information.
Q: What is the official information regarding the effect of Xalkori on the immune system?
A: Xalkori can reduce white blood cell counts, which are crucial components of the immune system needed for fighting infection. The specific reductions noted in official documents are neutropenia and lymphopenia.
Q: How is the long-term effectiveness of Xalkori generally monitored by physicians?
A: Long-term effectiveness is monitored by physicians through tracking for an objective response, meaning whether tumors have shrunk or stopped growing. This measurement, along with the duration of the response, helps determine if the medication continues to provide clinical benefit.
Q: Is Xalkori the first treatment option for ALK-positive non-small cell lung cancer?
A: Clinical trial data supporting Xalkori’s approval demonstrated superior progression-free survival when compared to standard chemotherapy in patients who had not been previously treated for ALK-positive NSCLC. This evidence established the basis for its consideration as an initial treatment option for this patient population.
Q: Does Xalkori cause a burning sensation or rash on the skin?
A: Yes, rash is listed as a common adverse reaction in official product information. Furthermore, a burning sensation has been reported as a type of peripheral neuropathy associated with the drug.
